v3.24.2.u1
PRODUCT REVENUE, NET
6 Months Ended
Jun. 30, 2024
PRODUCT REVENUE, NET  
PRODUCT REVENUE, NET

NOTE 4—PRODUCT REVENUE, NET

The Company’s product revenue, net was generated from sales of DANYELZA and consists of the following (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended June 30, 

​

Six months ended June 30, 

​

    

2024

​

2023

    

2024

​

2023

​

​

(in thousands)

Product revenue, net by geographical location:

​

​

​

​

​

​

​

​

​

​

​

​

United States

​

$

15,226

​

$

15,851

​

$

33,836

​

$

32,685

International:

​

​

​

​

​

​

​

​

​

​

​

​

Western Europe

​

​

2,076

​

​

—

​

​

2,076

​

​

2,516

Eastern Asia

​

​

3,415

​

​

4,553

​

​

3,466

​

​

5,304

Latin America

​

​

1,749

​

​

—

​

​

2,257

​

​

—

Other regions

​

​

332

​

​

347

​

​

594

​

​

497

Total international

​

​

7,572

​

​

4,900

​

​

8,393

​

​

8,317

Total product revenue, net

​

$

22,798

​

$

20,751

​

$

42,229

​

$

41,002

​

The Company recognized royalty revenue from the distribution partners of $2,756,000 and $2,620,000 in the three months ended June 30, 2024 and 2023, respectively. The Company recognized royalty revenue from the distribution partners of $3,218,000 and $3,387,000 in the six months ended June 30, 2024 and 2023, respectively.

Product sales to certain customers that accounted for more than 10% of total product revenue, net, for the three and six months ended June 30, 2024 and 2023 consists of the following:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended June 30, 

​

Six months ended June 30, 

​

    

2024

​

2023

    

2024

​

2023

​

​

​

McKesson

​

38

%

​

46

%

​

43

%

​

44

%

Cardinal Health

​

18

​

​

12

​

​

19

​

​

12

​

AmerisouceBergen

​

11

​

​

18

​

​

17

​

​

23

​

SciClone

​

15

​

​

20

​

​

8

​

​

12

​

​

As of June 30, 2024, the Company had recorded on the Consolidated Balance Sheets accounts receivable of approximately $22,191,000, of which $3,431,000 represents an unbilled portion to which the Company has unconditional rights to collect the consideration, and accrued liabilities of $300,000 both related to product sales to the Company’s distributor in Western Europe, WEP.

Revenue from product sales is recorded as net of applicable provisions for rebates, chargebacks, discounts, distribution-related fees and other sales-related deductions. Accruals for chargebacks and discounts are recorded as a direct reduction to accounts receivable. Accruals for rebates, distribution-related fees without contractual right of offset and other sales-related deductions are recorded within accrued liabilities. As of June 30, 2024, the Company had recorded accounts receivable allowances of approximately $613,000 and accrued liabilities of approximately $1,681,000 related to product sales. As of December 31, 2023, the Company had recorded accounts receivable allowances of approximately $492,000 and accrued liabilities of $2,309,000 related to product sales.

An analysis of the change in reserves for discounts and allowances is summarized as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

​

​

Contractual

 

    

​

​

    

​

​

​

​

​

Allowances and

​

​

​

​

​

​

​

Discounts

​

Government Rebates

 

Returns

​

Total

​

​

Balance December 31, 2023

$

41

​

$

2,694

​

$

66

​

$

2,801

Current provisions relating to sales in current year

​

187

​

​

5,223

​

​

7

​

​

5,417

Payments/credits relating to sales in current year

​

(156)

​

​

(5,386)

​

​

—

​

​

(5,542)

Change in estimate related to sales in the prior year

​

—

​

​

(382)

​

​

—

​

​

(382)

Balance June 30, 2024

$

72

​

$

2,149

​

$

73

​

$

2,294

​